Specialty pharmaceuticals account for over 50% of pharmacy benefit spending in the United States, and they often have complex and unique distribution, administration, and reimbursement protocols.

• Use this glossary to educate yourself and others within your organization about terminology related to specialty medications.
• Explore how specialty pharmacy models are changing to meet market demands and what it will take to succeed in the future.
• Learn strategies to improve reimbursement for provider-administered specialty medications amidst increasing prior-authorization requirements and denials.

Diagnostic labs are involved in one-third of all patient encounters and play a critical role in driving patient care decisions.

• Understanding the lab landscape is essential to manage the growing costs and complexity related to patient diagnostic testing.
• Genetic testing is a rapidly growing driver of lab spending – and providers, health plans, and diagnostics companies must reassess their approaches to genetic testing to take advantage of the tests’ full value.
• Health systems and health plans are looking for lab partners that can help them navigate the challenges associated with managing lab spend.

Pharmacy benefit managers (PBMs) play a crucial role in drug selection and pricing, yet they often remain hidden.

• Gain a deeper understanding of the evolving role and influence of pharmacy benefit managers in drug-related decisions.
• Track industry moves shaping the future of PBMs within the healthcare system and pharmaceutical supply chain.
• Learn about the interconnections between PBMs, specialty pharmacies, insurers, and pharmaceutical manufacturers.

Infusion care is evolving as a strategic battleground between healthcare stakeholders, from traditional providers and health plans to emerging, private-equity-backed corporate franchises.

• Emerging sites of care, including home infusion and community-based infusion suites, are projected to experience significant growth in the coming years.
• Health systems are diversifying their infusion capabilities to both accommodate and push back against health plan cost management policies.
• Private equity firms are investing in home infusion providers, capitalizing on the high demand for these services and anticipating potential profits.